$NBIX News

BMO Capital Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $170

Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen

3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)

Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Neurocrine Biosciences (NBIX) Stock Looks Fair On Earnings But Pricey Versus Biotechs

Neurocrine Biosciences (NBIX) Could Be 8% Undervalued Following New Phase 2 Study

Neurocrine Biosciences (NBIX) Starts Phase 2 CAH Study In Children Under 4

Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?

RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $195

Reasons Why Investors Should Consider Betting on Neurocrine Stock

Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screen

Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno

Neurocrine (NBIX) Reports Clinically Meaningful Benefits in 94% of Patients Treated for Tardive Dyskinesia

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Initiates Phase 2 Clinical Study To Assess Crinecerfont In Children Aged 3 Months To Under 4 Years With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know

Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setup

Neurocrine Biosciences' Ingrezza Momentum Seen Supporting 2026 Guidance Upgrade, UBS Says

Neurocrine Biosciences (NBIX) Is Up 6.5% After CRENESSITY Shows Broad CAH Benefits at ENDO 2026 – Has The Bull Case Changed?